Five proteins are significant predictors of metabolic dysfunction-associated steatotic liver disease (MASLD), according to a study presented at the 2025 Digestive Disease Week, held from May 3 to 6 in ...

How alterations in cell metabolism translate into specific developmental gene programs remains a major question. This study ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

DGIST Department of New Biology Professor Yea Kyungmoo and his research team have developed a next-generation exosome-based ...

Michael Tadros, MD, MPH, discusses how lessons learned from HCV treatment could improve the management of metabolic ...

The future of treating metabolic dysfunction–associated steatohepatitis (MASH) looks brighter than ever, says Naim Alkhouri, MD, as data emerges on newly developed interventions.

The biotech is using AI and a trove of health data to better understand why certain conditions progress and intervene ...

Doer Biologics begins patient dosing in phase 2 study of DR10624 to treat metabolic dysfunction-associated steatotic liver disease and MASH: Hangzhou, China Thursday, April 24, 20 ...

MetaVia Inc. ( Nasdaq: MTVA) announced that a late-breaking abstract highlighting Phase 2a data from its DA-1241 program in presumed metabolic dysfunction-associated steatohepatitis (MASH) has been ...

Researchers at Mayo Clinic's Center for Individualized Medicine have discovered a rare genetic variant that can directly ...

QPS, a leading global contract research organization (CRO) specializing in preclinical and clinical drug development services ...

Boston Pharmaceuticals, a clinical-stage biopharmaceutical company developing efimosfermin alfa, an investigational, once-monthly FGF21 analogue for the treatment of metabolic dysfunction-associated ...